Clinsys(R) Redefines Resource Services with the Launch of Clinsys ALTERNA(TM)

BEDMINSTER, N.J., April 10 /PRNewswire/ -- Clinsys Clinical Research, a therapeutically focused global contract research organization, today announced the launch of Clinsys ALTERNA, which utilizes its Global Project Solution(R) (Clinsys GPS(R)) to augment clinical resource services. The new division demonstrates Clinsys' commitment to aligning its service offerings with its sponsors' and the life sciences industry's continuously evolving staffing needs.

Clinsys ALTERNA provides customized Phase I-IV clinical trial alternative solutions to the conventional outsourcing model. The division is a core element of Clinsys GPS, a unique, highly effective and proven integrated project management solution that brings the sponsor and the Clinsys project teams together to collaborate and agree on all aspects of the clinical study- before, during and after-to ensure the project's success.

"Clinsys ALTERNA provides a targeted and flexible clinical resourcing model that adapts to best serve a sponsor's trial management needs," said David E. Williams, Chief Executive Officer of Clinsys. "We devoted the time and energy required to approach the evolution of resourcing in an innovative way that both maximizes efficiencies and decreases deliverable timelines."

Drawing on extensive clinical research experience, Clinsys ALTERNA delivers a custom-designed, time-sensitive clinical solution that enables sponsors to engage its services in site management, clinical monitoring, project management, drug safety, regulatory and medical writing on a contract basis. Clinsys ALTERNA combines therapeutic expertise, clinical screening, performance reviews, site references and global reach to offer clients the most dependable and comprehensive alternative approach to their trial needs. Visit clinsysalterna.com for more information.

About Clinsys Clinical Research, Inc.

Clinsys Clinical Research, Inc.(R), is a therapeutically focused clinical research organization and a Jubilant Organosys company headquartered in Bedminster, New Jersey. Clinsys has operations in Raleigh, North Carolina; Philadelphia, Pennsylvania; Dusseldorf, Germany; Noida and Bangalore, India. Clinsys provides pharmaceutical, biotechnology and medical device companies a broad range of clinical research services in support of Phase I-IV drug development: project management, medical and clinical monitoring, investigator and patient recruitment, site management, biostatistics, data management, drug safety, quality assurance, regulatory services and medical writing services. Clinsys has expertise in a wide range of highly specialized therapeutic areas, including oncology, cardiovascular, central nervous system, dermatology, respiratory and allergy/immunology. Clinsys Clinical Research, Ltd., with operations in Noida and Bangalore, India, provides extensive clinical research services for Phase I-IV drug development, and operates a clinical pharmacology unit performing bioavailability and bioequivalence studies as well as bioanalytical sample analysis, clinical laboratory and pathology services. Clinsys ALTERNA(TM) (clinsysalterna.com), a division of Clinsys Clinical Research, Inc., partners with clients globally to provide customized Phase I- IV clinical trial alternative solutions to the conventional outsourcing model. For more information, visit clinsys.com.

Clinsys, Clinsys Clinical Research, Inc., Clinsys GPS and Global Project Solution are registered trademarks of Clinsys Clinical Research, Inc. Clinsys ALTERNA registration pending. (C) Copyright 2008 Clinsys Clinical Research, Inc. All rights reserved.

SOURCE Clinsys Clinical Research, Inc.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.